Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

IMPORTANCE: Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundari...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Cardiol
Autors principals: Giugliano, Robert P., Keech, Anthony, Murphy, Sabina A., Huber, Kurt, Tokgozoglu, S. Lale, Lewis, Basil S., Ferreira, Jorge, Pineda, Armando Lira, Somaratne, Ransi, Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2017
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815002/
https://ncbi.nlm.nih.gov/pubmed/29117276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3944
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars